Allogene Therapeutics (ALLO) Interest Expenses (2018 - 2026)

Allogene Therapeutics has reported Interest Expenses for 9 years, with the latest figure at $102.7 million in Q1 2026.

• Quarterly Interest Expenses rose 629.38% year-over-year to $102.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $102.7 million (up 629.38% YoY) and the FY2025 annual result came in at $12.9 million, down 97.1% from the prior year.
• Interest Expenses improved to $102.7 million in Q1 2026 per ALLO's latest filing, from $12.1 million in the prior quarter.
• Over five years, Interest Expenses peaked at $143.4 million in Q3 2022 and troughed at -$6.0 million in Q4 2023.
• A 5-year average of $34.4 million and a median of $14.1 million in 2025 frame the typical range for Interest Expenses.
• The sharpest annual moves came in 2023 and 2025: Interest Expenses slumped 186.96% in 2023, then jumped 14885.19% in 2025.
• Over 5 years, Interest Expenses stood at $6.9 million in 2022, then tumbled by 186.96% to -$6.0 million in 2023, then jumped by 101.35% to $81000.0 in 2024, then surged by 14885.19% to $12.1 million in 2025, then soared by 746.02% to $102.7 million in 2026.
• According to Business Quant data, Interest Expenses over the past three periods registered $102.7 million, $12.1 million, and $24.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.